Verona Pharma plc VRNA
Set alert
106.91 0.00 0.00%
At close · Oct 7
106.91 Day range 106.91
31.60 52-week range 106.93
- YTD
- +130.21%
- 1 year
- +233.99%
- Open
- 106.91
- Prev close
- 106.91
- Mkt cap
- 9.09B
- Vol
- 1.87M
- Avg vol
- 1.69M
- EPS
- -1.04
- P/E
- 872.73
- Div yield
- 0.00%
More statistics
- Low
- 106.91
- High
- 106.91
- Forward P/E
- -381.82
- Beta
- 0.05
- Short ratio
- 1.56
- Inst. own
- 92.23%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 3, 2025
- 50-d avg
- 105.95
- 200-d avg
- 79.84
- 1y target
- 0.00
2Y chart
Events in this range
- Jul 1, 2025Rating: Wolfe Research · — → Outperform
- Jul 9, 2025Downgrade: Canaccord Genuity · Buy → Hold
- Jul 9, 2025Downgrade: Jefferies · Buy → Hold
- Jul 10, 2025Downgrade: BTIG · Buy → Neutral
- Jul 10, 2025Downgrade: Wells Fargo · Overweight → Equal-Weight
- Jul 14, 2025Downgrade: HC Wainwright & Co. · Buy → Neutral
Signals (77)
| Name | Date | Ago |
|---|---|---|
| RSI: Overbought | Oct 1, 2025 | 1 year ago |
| RSI: Overbought | Sep 25, 2025 | 1 year ago |
| RSI: Overbought | Sep 2, 2025 | 1 year ago |
| RSI: Overbought | Aug 20, 2025 | 1 year ago |
| RSI: Overbought | Aug 18, 2025 | 1 year ago |
| MACD: Sell Signal | Jul 23, 2025 | 1 year ago |
| MACD: Buy Signal | Jul 10, 2025 | 1 year ago |
| RSI: Overbought | Jul 9, 2025 | 1 year ago |
| MACD: Sell Signal | Jun 26, 2025 | 1 year ago |
| RSI: Overbought | May 30, 2025 | 1 year ago |
| MACD: Buy Signal | May 19, 2025 | 1 year ago |
| SMA: Bullish | May 12, 2025 | 1 year ago |
| SMA: Bearish | May 9, 2025 | 1 year ago |
| MACD: Sell Signal | May 9, 2025 | 1 year ago |
| RSI: Overbought | Apr 29, 2025 | 1 year ago |
| SMA: Bullish | Apr 23, 2025 | 1 year ago |
| MACD: Buy Signal | Apr 17, 2025 | 1 year ago |
| SMA: Bearish | Apr 1, 2025 | 1 year ago |
| MACD: Sell Signal | Mar 3, 2025 | 1 year ago |
| MACD: Buy Signal | Feb 28, 2025 | 1 year ago |
| MACD: Sell Signal | Feb 25, 2025 | 1 year ago |
| RSI: Overbought | Feb 14, 2025 | 1 year ago |
| MACD: Buy Signal | Feb 12, 2025 | 1 year ago |
| RSI: Overbought | Feb 12, 2025 | 1 year ago |
| MACD: Sell Signal | Feb 11, 2025 | 1 year ago |
| RSI: Overbought | Feb 3, 2025 | 1 year ago |
| MACD: Buy Signal | Jan 15, 2025 | 1 year ago |
| MACD: Sell Signal | Jan 10, 2025 | 1 year ago |
| RSI: Overbought | Jan 2, 2025 | 1 year ago |
| RSI: Overbought | Dec 30, 2024 | 1 year ago |
| RSI: Overbought | Dec 26, 2024 | 1 year ago |
| MACD: Buy Signal | Dec 23, 2024 | 1 year ago |
| MACD: Sell Signal | Dec 18, 2024 | 1 year ago |
| MACD: Buy Signal | Dec 16, 2024 | 1 year ago |
| MACD: Sell Signal | Dec 2, 2024 | 1 year ago |
| MACD: Buy Signal | Nov 26, 2024 | 1 year ago |
| MACD: Sell Signal | Nov 14, 2024 | 1 year ago |
| MACD: Buy Signal | Nov 4, 2024 | 1 year ago |
| RSI: Overbought | Nov 4, 2024 | 1 year ago |
| MACD: Sell Signal | Oct 25, 2024 | 2 years ago |
| RSI: Overbought | Oct 14, 2024 | 2 years ago |
| MACD: Buy Signal | Oct 4, 2024 | 2 years ago |
| MACD: Sell Signal | Sep 18, 2024 | 2 years ago |
| MACD: Buy Signal | Sep 12, 2024 | 2 years ago |
| RSI: Overbought | Sep 11, 2024 | 2 years ago |
| MACD: Sell Signal | Aug 27, 2024 | 2 years ago |
| MACD: Buy Signal | Aug 13, 2024 | 2 years ago |
| RSI: Overbought | Aug 13, 2024 | 2 years ago |
| MACD: Sell Signal | Jul 29, 2024 | 2 years ago |
| RSI: Overbought | Jul 11, 2024 | 2 years ago |
| RSI: Overbought | Jun 17, 2024 | 2 years ago |
| RSI: Overbought | Jun 13, 2024 | 2 years ago |
| SMA: Bullish | Jun 12, 2024 | 2 years ago |
| MACD: Buy Signal | Jun 5, 2024 | 2 years ago |
| RSI: Oversold | May 16, 2024 | 2 years ago |
| RSI: Oversold | May 13, 2024 | 2 years ago |
| MACD: Sell Signal | May 6, 2024 | 2 years ago |
| MACD: Buy Signal | May 3, 2024 | 2 years ago |
| MACD: Sell Signal | Apr 19, 2024 | 2 years ago |
| MACD: Buy Signal | Apr 16, 2024 | 2 years ago |
| MACD: Sell Signal | Apr 15, 2024 | 2 years ago |
| SMA: Bearish | Apr 9, 2024 | 2 years ago |
| SMA: Bullish | Apr 5, 2024 | 2 years ago |
| MACD: Buy Signal | Mar 26, 2024 | 2 years ago |
| MACD: Sell Signal | Mar 7, 2024 | 2 years ago |
| SMA: Bearish | Mar 4, 2024 | 2 years ago |
| SMA: Bullish | Mar 1, 2024 | 2 years ago |
| SMA: Bearish | Feb 28, 2024 | 2 years ago |
| SMA: Bullish | Feb 27, 2024 | 2 years ago |
| MACD: Buy Signal | Feb 27, 2024 | 2 years ago |
| SMA: Bearish | Feb 15, 2024 | 2 years ago |
| SMA: Bullish | Feb 14, 2024 | 2 years ago |
| SMA: Bearish | Feb 7, 2024 | 2 years ago |
| MACD: Sell Signal | Jan 9, 2024 | 2 years ago |
| RSI: Overbought | Dec 26, 2023 | 2 years ago |
| RSI: Overbought | Dec 15, 2023 | 2 years ago |
| MACD: Buy Signal | Dec 11, 2023 | 2 years ago |
Key statistics
- Market cap
- 9.09B
- Enterprise value
- 73.52B
- Trailing P/E
- 0.00
- Forward P/E
- -381.82
- PEG ratio
- 0.00
- Price / sales
- 40.98
- Price / book
- 33.04
- EPS (TTM)
- -1.04
- Beta
- 0.05
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- -36.63%
- Revenue (TTM)
- 221.67M
- Revenue growth
- 0.00%
- Free cash flow
- -57.39M
- Total cash
- 438.02M
- Total debt
- 244.37M
- Return on equity
- -36.36%
- Shares outstanding
- 84.98M
- Short % of float
- 2.44%
- 50-day average
- 105.95
- 200-day average
- 79.84
Analyst view
Consensus: hold
Hold
Price target (mean) 0.00
Ratings (0m) 6 0 buy · 6 hold · 0 sell
- Strong buy0
- Buy0
- Hold6
- Sell0
- Strong sell0
Next earnings
Nov 3, 2025
Expected Nov 3, 2025. Consensus EPS estimate 0.00.
Financials — quick view
VRNA Revenue — quarterly 103.14M
VRNA Net income — quarterly 11.92M
VRNA EPS — quarterly 0.16
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 3, 2025 | Sep 1, 2025 | 0.16 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jul 14, 2025 | HC Wainwright & Co. | down | Buy | Neutral |
| Jul 10, 2025 | Wells Fargo | down | Overweight | Equal-Weight |
| Jul 10, 2025 | BTIG | down | Buy | Neutral |
| Jul 9, 2025 | Jefferies | down | Buy | Hold |
| Jul 9, 2025 | Canaccord Genuity | down | Buy | Hold |
| Jul 1, 2025 | Wolfe Research | init | — | Outperform |
About Verona Pharma plc
Verona Pharma plc, a biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company offers Ohtuvayre, a dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that combines bronchodilator and non-steroidal anti-inflammatory effects for the maintenance treatment of chronic obstructive pulmonary disease, as well as cystic fibrosis and asthma. Verona Pharma plc was formerly known as Isis Resources plc and changed its name to Verona Pharma plc in September 2006. The company was incorporated in 2005 and is based in London, the United Kingdom. As of October 7, 2025, Verona Pharma plc operates as a subsidiary of Merck Sharp & Dohme LLC.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United Kingdom
- Website
- veronapharma.com
News
- Oracle Corp Sees Significant Reduction in Jeremy Grantham's Portfolio
- Mueller Industries Inc: A Key Focus in Mario Gabelli's Latest 13F Filing
- The Year-End 2025 Biotech Rally And What It Means For 2026
- Oracle Corp Sees Significant Reduction in Jeremy Grantham's Portfolio
- Sumitomo Mitsui Trust Group Inc. Buys 205 Shares of Verona Pharma PLC American Depositary Share $VRNA
- Verona Pharma PLC American Depositary Share (VRNA) Projected to Post Earnings on Monday
- Acquisition of Verona by MSD Approved by the High Court of Justice of England and Wales
- Shareholders of Verona Pharma Approve Proposed Acquisition by Merck
- Verona Pharma to Present Additional Analyses of the Phase 3 ENHANCE Studies in COPD at ERS International Congress 2025
- All You Need to Know About Verona Pharma (VRNA) Rating Upgrade to Buy
Your note
Sign in to keep a note on VRNA — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ACKERMANN CHRISTINA M | Director | Conversion of Exercise of derivative security | Oct 6, 2025 | 0 |
| AUSTWICK MICHAEL | Director | Conversion of Exercise of derivative security | Oct 6, 2025 | 0 |
| DESCHAMPS LISA | Director | Conversion of Exercise of derivative security | Oct 6, 2025 | 0 |
| EDWARDS MARTIN | Director | Conversion of Exercise of derivative security | Oct 6, 2025 | 0 |
| HAHN MARK W | Chief Financial Officer | Conversion of Exercise of derivative security | Oct 6, 2025 | 0 |
| RICKARD KATHLEEN A | Officer | Conversion of Exercise of derivative security | Oct 6, 2025 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Janus Henderson Group PLC | 7.12% | 6,134,405 | 655.83M | Jun 29, 2025 |
| Perceptive Advisors Llc | 6.39% | 5,507,591 | 588.82M | Jun 29, 2025 |
| Darwin Global Management, Ltd. | 4.79% | 4,129,618 | 441.50M | Jun 29, 2025 |
| Frazier Life Sciences Management, L.P. | 3.93% | 3,383,950 | 361.78M | Jun 29, 2025 |
| RTW Investments LP | 3.54% | 3,051,878 | 326.28M | Jun 29, 2025 |
| Eventide Asset Management LLC | 3.15% | 2,715,324 | 290.30M | Jun 29, 2025 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| MUTUAL FUND SERIES TRUST-Eventide Gilead Fund | 2.19% | 1,889,627 | 202.02M | Jun 29, 2025 |
| T. Rowe Price Health Sciences Fund, Inc. | 1.57% | 1,357,044 | 145.08M | Jun 29, 2025 |
| JANUS INVESTMENT FUND-Janus Henderson Global Life Sciences Fund | 1.09% | 936,802 | 100.15M | Jun 29, 2025 |
| Manager Directed Portfolios-Hood River Small-Cap Growth Fund | 0.95% | 820,644 | 87.74M | Jul 30, 2025 |
| MUTUAL FUND SERIES TRUST-Eventide Healthcare & Life Sciences Fund | 0.94% | 809,112 | 86.50M | Jun 29, 2025 |
| Putnam Funds Trust-Putnam Small Cap Growth Fund | 0.85% | 734,132 | 78.49M | Jun 29, 2025 |